Michihide Tokuhira

Summary

Affiliation: Saitama Medical School
Country: Japan

Publications

  1. doi request reprint Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis
    Michihide Tokuhira
    Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Leuk Lymphoma 53:616-23. 2012
  2. ncbi request reprint De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation
    Michihide Tokuhira
    Division of Hematology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Am J Hematol 82:162-7. 2007
  3. doi request reprint Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma
    Michihide Tokuhira
    Department of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama 350 8550, Japan
    Leuk Res 35:591-7. 2011
  4. doi request reprint Severe degenerative change of multiple organs mediated by chronic active Epstein-Barr virus infection with infected T-cell expansion
    Michihide Tokuhira
    Division of Hematology, Department of Internal Medicine, Saitama Medical Center, 1981 Kamodatsujido, Kawagoe, Saitama 350 8550, Japan
    Int J Hematol 87:520-6. 2008
  5. pmc Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report
    Michihide Tokuhira
    Division of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    J Hematol Oncol 2:27. 2009
  6. doi request reprint Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era
    Kyoko Hanzawa
    Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
    Leuk Lymphoma 51:2054-62. 2010
  7. ncbi request reprint Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis
    Hideto Kameda
    Division of Rheumatology Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Kawagoe, Japan
    J Rheumatol 32:1719-26. 2005
  8. doi request reprint Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma
    Morihiro Higashi
    a Department of Pathology, Saitama, Japan
    Leuk Lymphoma 57:161-6. 2016
  9. ncbi request reprint [Acute-onset eosinophilic leukemia associated with tumor lysis syndrome after imatinib and steroid pulse therapy]
    Tomoe Nemoto
    Department of Hematology, Saitama Medical Center, Saitama Medical University
    Rinsho Ketsueki 51:326-31. 2010
  10. doi request reprint Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury
    Reiko Watanabe
    Department of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350 8550, Japan
    Int J Hematol 105:100-103. 2017

Collaborators

Detail Information

Publications17

  1. doi request reprint Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis
    Michihide Tokuhira
    Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Leuk Lymphoma 53:616-23. 2012
    ..Regarding RA treatment, various anti-RA drugs were given to the patients after developing LPDs, including MTX, but no recurrent patients were documented...
  2. ncbi request reprint De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantation
    Michihide Tokuhira
    Division of Hematology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    Am J Hematol 82:162-7. 2007
    ..To the best of our knowledge, this is the first report of a case of de novo CD5+ DLBCL showing marked elevation of the PB basophil count...
  3. doi request reprint Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma
    Michihide Tokuhira
    Department of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama 350 8550, Japan
    Leuk Res 35:591-7. 2011
    ..The treatment-related toxicities of this strategy were mild and tolerable. To our knowledge, this is the first report of the administration of bortezomib at intervals longer than once weekly...
  4. doi request reprint Severe degenerative change of multiple organs mediated by chronic active Epstein-Barr virus infection with infected T-cell expansion
    Michihide Tokuhira
    Division of Hematology, Department of Internal Medicine, Saitama Medical Center, 1981 Kamodatsujido, Kawagoe, Saitama 350 8550, Japan
    Int J Hematol 87:520-6. 2008
    ..The autopsy results of this case suggest the possibility of EBV-mediated, severe degenerative changes in multiple organs...
  5. pmc Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein-Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report
    Michihide Tokuhira
    Division of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
    J Hematol Oncol 2:27. 2009
    ..In this report we present a case of an autopsy-proven co-existence of AML-MLD and EBV-associated T-LPD in a patient with RA...
  6. doi request reprint Y-box binding protein-1 expression in diffuse large B-cell lymphoma: an impact on prognosis in the rituximab era
    Kyoko Hanzawa
    Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
    Leuk Lymphoma 51:2054-62. 2010
    ....
  7. ncbi request reprint Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis
    Hideto Kameda
    Division of Rheumatology Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Kawagoe, Japan
    J Rheumatol 32:1719-26. 2005
    ..Our objective was to improve the survival rate of patients with A/SIP associated with PM/DM; and to characterize patients with PM/DM who are at high risk of developing A/SIP...
  8. doi request reprint Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma
    Morihiro Higashi
    a Department of Pathology, Saitama, Japan
    Leuk Lymphoma 57:161-6. 2016
    ..05). These data suggest that loss of HLA-DR expression in DLBCL decreases the ratio of helper T-cell within the T-cell population in the tumor microenvironment and might contribute to escape from immunosurveillance. ..
  9. ncbi request reprint [Acute-onset eosinophilic leukemia associated with tumor lysis syndrome after imatinib and steroid pulse therapy]
    Tomoe Nemoto
    Department of Hematology, Saitama Medical Center, Saitama Medical University
    Rinsho Ketsueki 51:326-31. 2010
    ..Supportive therapies such as artificial dialysis and transfusions were conducted, but unfortunately she died because of alveolar hemorrhage...
  10. doi request reprint Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury
    Reiko Watanabe
    Department of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350 8550, Japan
    Int J Hematol 105:100-103. 2017
    ..Our data suggest that the early use of romiplostim is effective in emergency cases of newly diagnosed ITP with life-threatening bleeding, which is refractory to standard treatment...
  11. doi request reprint [Cardiac and breast diffuse large B-cell lymphoma with pericardial effusion and AV-block]
    Tatsuki Tomikawa
    Department of Hematology, Saitama Medical Center, Saitama Medical University
    Rinsho Ketsueki 56:9-15. 2015
    ..This case demonstrates that rapid and appropriate diagnosis, and immediate intensive chemotherapy followed by PBSCT might be necessary for the treatment of extranodal lymphoma indicative of a poor prognosis. ..
  12. pmc TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities
    Morihiko Sagawa
    Department of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
    Cancer Sci 106:438-46. 2015
    ..In conclusion, TM-233 might be a more potent NF-κB inhibitor than ACA, and could overcome bortezomib resistance in myeloma cells. ..
  13. doi request reprint Current approaches for the treatment of multiple myeloma
    Reiko Watanabe
    Division of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350 8550, Japan
    Int J Hematol 97:333-44. 2013
    ..The present paper will review clinical evidence from previous and ongoing studies to explore issues related to these questions...
  14. ncbi request reprint Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy
    Takehiko Mori
    Second Department of Internal Medicine, Saitama Medical Center, Saitama Medical School, Kawagoe, Saitama, Japan
    J Rheumatol 31:1349-51. 2004
    ..To evaluate the incidence and effect of cytomegalovirus (CMV) reactivation in patients with inflammatory connective tissue diseases (CTD) undergoing immunosuppressive therapy...
  15. doi request reprint Mechanisms of drug resistance and sensitivity concerning novel agents for multiple myeloma
    Michihide Tokuhira
    Saitama Medical Center, Saitama Medical University, Department of Hematology
    Rinsho Ketsueki 57:563-74. 2016
    ..In addition, based on the improved OS over 10 years and the low continuation rate of standard therapy in frail patients, a stratified strategy has the potential to provide total therapy. ..
  16. ncbi request reprint Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma
    Jun Ichi Tamaru
    Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
    Leuk Lymphoma 48:1127-38. 2007
    ..However, the patients with Hodgkin-like ALCL with CHL-immunophenotype (PAX-5/BSAP-positive and negative for Oct.2 and/or BOB.1) did not have a favorable outcome, with a 5-year OS rate of 58%...
  17. doi request reprint New therapeutic approaches to acute myeloid leukemia
    Hideo Uchida
    TEPCO Hospital, Department of Internal Medicine, Shinjuku ku, Tokyo 160 0016, Japan
    Expert Opin Drug Discov 3:689-706. 2008
    ..Conclusion: In the future, in addition to performing therapeutic trials of these agents, it will be important to identify other highly specific therapeutic agents based on our evolving understanding of the biology of AML...